linjc16/ctgov huggingface dataset:
Relationship Between Dopamine Genetics, Food Reinforcement, Energy Intake and Obesity

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether the presentation of various foods produces an increase or decrease in responses on a motivational computer task. In addition, the study determines if energy intake or motivation to obtain food is related to the dopamine receptor genotype.

Detailed Description
-----------------
One of the most important research areas in obesity is developing a better understanding of individual differences in factors that influence excess energy intake and positive energy balance. One key to understanding these individual differences is determining what factors underlie the motivation to eat. We have demonstrated in a series of studies that obese adults and children are more motivated to work for palatable, favorite foods than leaner peers and that those high in food reinforcement consume more food in an ad libitum eating task than those who do not find food as reinforcing. Dopamine (DA) is one of the major neurotransmitters involved in establishing the reinforcing value of food, and low levels of dopamine activity and a reduction in the number of DA receptors is associated with obesity. The general aim of the proposed research is to build upon this research to examine relationships between food reinforcement, obesity, and polymorphisms of genes within the dopaminergic system.

Official Title
-----------------
Food Reinforcement Genotype Interactions and Eating

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-smokers 18-50 years of age No known eating disorder Moderate liking for study foods No current diagnosis of psychiatric disorder (e.g., anxiety or depression) Not on medications that would interfere with appetite (e.g., methylphenidate) or dopaminergic activity Non-diabetics Exclusion Criteria: Smoker Pregnant women Current diagnosis of a psychiatric or eating disorder Dietary restrictions that would interfere with participation On medications that could interfere with appetite or olfactory responsiveness or use of antidepressants or any medication or dietary supplement that could affect appetite or dopaminergic activity Excessive use of alcohol (>21 drinks/week), alcoholism,current addiction to opiates, cocaine or stimulants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obese/Non-obese<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Food Reinforcement, Energy Intake, Obesity, Dopamine
Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer.

Detailed Description
-----------------
OBJECTIVES: Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in patients with resectable non-small cell lung cancer. Determine the treatment-related toxicity in patients treated with this therapy. Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients. OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection. PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.

Official Title
-----------------
Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Procedure: conventional surgery
* Procedure: radiofrequency ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of malignant non-small cell lung cancer (NSCLC) Intraoperative needle biopsy confirmation allowed Resectable disease (stage I or II) All tissue to be treated by radiofrequency tumor ablation must be completely contained within boundaries of planned lung resection Medically fit to undergo lung resection PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: No prior or concurrent biologic therapy Chemotherapy: No prior or concurrent chemotherapy Endocrine therapy: No prior or concurrent endocrine therapy Radiotherapy: No prior or concurrent radiotherapy Surgery: See Disease Characteristics Other: No other prior therapy for NSCLC

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: conventional surgery|nan|
|Procedure: radiofrequency ablation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage I non-small cell lung cancer, stage II non-small cell lung cancer
Effect of Acupuncture on Intraocular Pressure

Study Overview
=================
Brief Summary
-----------------
To evaluate the short-term effect of acupuncture on the intraocular pressure (IOP). Methods: A randomized controlled trial. Healthy volunteers will be randomly allocated to three groups: Acupuncture group - will be submitted to a 20-minute session of acupuncture with needles inserted in specific points (Tong Zi Liao, Yang Bai and Jing Ming); Sham group - will be submitted to a 20- minute session of acupuncture with needles inserted in false points located 1 cm from true points in areas without acupuncture's meridians; and Control group - no intervention. IOP measurement by a masked investigator using Goldmann applanation tonometry immediately before the intervention, as well as 30 minutes and 24 hours after the acupuncture.

Official Title
-----------------
Effect of Acupuncture on Intraocular Pressure

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Acupuncture
* Other: Sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteers Exclusion Criteria: glaucoma past intraocular surgery corneal alterations medications that interferes with the intraocular pressure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: 2<br>20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians | Other: Sham<br>* 20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians<br>|
| Active Comparator: 1<br>20-minute session of acupuncture with needles inserted in specific points (Tong Zi Liao, Yang Bai and Jing Ming) | Other: Acupuncture<br>* 20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming<br>|
| No Intervention: 3<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| variation of the intraocular pressure |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intraocular Pressure, Acupuncture, Healthy Volunteers
SPARQ and Core Proprioception

Study Overview
=================
Brief Summary
-----------------
The purpose of this investigation is to determine the relationship of core stability to core proprioception

Detailed Description
-----------------
As no previous research has been reported correlating the SPARQtm method of athletic performance with the McGill Side Bridge test and core joint position error, this study is designed as a pilot. The subject's core stability will be measured with the SPARQtm method of athletic performance and the McGill Side Bridge test for core stability. Core proprioception will be determined using the standard test for proprioception, Joint Position Error (JPE) testing, with the Skill Technologies motion capture device. All participants will receive the SPARQtm method of athletic performance testing, the McGill Side Bridge test for core stability and the core joint position error tests twice, one week apart.

Official Title
-----------------
The Relationship of Core Stability to Core Proprioception

Conditions
-----------------
Proprioception, Core Strength

Intervention / Treatment
-----------------
* Other: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: college student, staff, or faculty members; History of thoracic / lumbar injuries for inclusion into the injured group. No history of thoracic / lumbar injuries for inclusion into the normal group. Ages 20 to 50 History of previous athletic performance. Exclusion Criteria: Previous lower extremity injury, surgery, visual or vestibular condition affecting balance Current acute illness that have an adverse effect on balance or core strength Local infection, injury or other malignancy Any unstable joints of the lower extremity or spine Any Spinal manipulation within 48 hours Prescription medication or supplement that affects blood pressure Pregnancy Diagnosis of severe hypertension (200-161/120-100 mmHg) Incapable of exercise for 15 minutes without hortness of breath Heart failure, kidney diseases and mental disorders

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>male & female college students ages 20 to 50, asymptomatic normals | Other: No Intervention<br>* male & female college students ages 20 to 50, asymptomatic normals<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mcgill sidebridge test proprioception testing SPARQ testing |  | Two testing sessions one week apart. |
Effect of EECP on Anterior Ischemic Optic Neuropathy

Study Overview
=================
Brief Summary
-----------------
Enhanced External Counterpulsation(EECP) therapy may promote the recovery of visual function by improving the blood perfusion of eyes. The present study aims to investigate the effect of EECP on Anterior Ischemic Optic Neuropathy.

Detailed Description
-----------------
Patients with Anterior Ischemic Optic Neuropathy are randomized into two groups: one group receive standard medical treatment for ischemic optic neuropathy, the other group plus EECP therapy besides standard medical treatment.

Official Title
-----------------
Study of the Effect of EECP on Anterior Ischemic Optic Neuropathy

Conditions
-----------------
Anterior Ischemic Optic Neuropathy

Intervention / Treatment
-----------------
* Device: Enhanced external counterpulsation
* Drug: Aspirin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ischemic optic neuropathy within 1 month Exclusion Criteria: Hemorrhagic disease thrombophlebitis or infection lesions severe hypertensive patients Atrial fibrillation Aortic regurgitation

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Enhanced External conterpulsation<br>Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. | Device: Enhanced external counterpulsation<br>* EECP is performed for 1 hours every day, for a total of 36 hours.<br>* Other names: EECP;Drug: Aspirin<br>* Standard drug therapy<br>|
| Active Comparator: aspirin<br>The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy. | Drug: Aspirin<br>* Standard drug therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual acuity |  | 7 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ophthalmic artery blood flow velocity |  | 7 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
visual acuity, artery flow velocity, Enhanced External Counterpulsation, Ischemic, Optic Neuropathy
Clinical Performance Evaluation of the NeuMoDx™ FluA/FluB/RSV/Severe Acute Respiratory Syndrome-CoV-2 Assay

Study Overview
=================
Brief Summary
-----------------
To demonstrate the clinical performance of the NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay on the NeuMoDx Systems by determining clinical sensitivity and specificity of the Assay.

Detailed Description
-----------------
To evaluate the clinical performance of the NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay on the on the NeuMoDx™ 288 and 96 Molecular Systems, collectively referred to as NeuMoDx Systems. The results of this study will be used to support regulatory registration and product release in the US, Europe and other markets.

Official Title
-----------------
Multi-Center Clinical Performance Evaluation of the NeuMoDx™ FluA/FluB/RSV/Severe Acute Respiratory Syndrome-CoV-2 Assay on the NeuMoDx™ Molecular Systems

Conditions
-----------------
Respiratory Disease

Intervention / Treatment
-----------------
* Device: NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fresh specimens shall be collected from all comers across the study duration Collected from individuals of any age presenting with influenza-like illness (ILI) Nasopharyngeal (NP) swab specimen obtained using a flexible mini-tip flocked swab and collected into 3 mL Copan® Universal Transport Media (UTM) [Cat. No.305c] or Beckton Dickinson (BD™) Universal Viral Transport (UVT) [Cat. No. 220531] Minimum volume for residual specimen approximately 2 mL Fresh specimens to be tested within 3 days of collection. Fresh specimens to be stored under the recommended stability conditions (2-8°C). Exclusion Criteria: Required information unable to be obtained from associated medical chart. Specimens not fitting criteria outlined above.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay|The NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay (IUO) is a multiplexed, in vitro real-time Polymerase Chain Reaction assay, diagnostic test intended for the simultaneous qualitative detection and differentiation of Influenza A virus (Flu A), Influenza B virus (Flu B), Respiratory Syncytial Virus (RSV) and SARS-CoV-2 RNA|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive Percentage Agreement | positive percentage agreement | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Negative Percentage Agreement | negative percentage agreement | 6 months |
Setrox JS Master Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is the evaluation of safety and efficacy of the pacemaker lead Setrox JS.

Official Title
-----------------
Efficacy and Safety of the Setrox JS Lead (J=J-shaped, S=Screw)

Conditions
-----------------
Cardiac Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet the indications for pacemaker therapy Available for follow-up visits on a regular basis at the investigational site Contractual capability and ability to consent Age ≥18 years Exclusion Criteria: Meet one or more of the contraindications for pacemaker therapy Permanent atrial fibrillation Have a life expectancy of less than six months Cardiac surgery in the next six months Enrolled in another cardiac clinical investigation Have other medical devices that may interact with the implanted pacemaker Pregnant and breast-feeding women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serious Adverse Device Effect rate |  | 6 months | 
| Atrial pacing threshold from Setrox JS at 3 month follow-up < 1.0V |  | 3 months |
Sclerotherapy of Internal Spermatic Veins in Patients With Varicocele and Localized Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
Patients with varicocele in whon early prostate cancer will be found will undergo venographic embolization of both spermatic veins. The study hypothesis is that this procedure will induce a gradual regression of the prostate volume that may decrease prostate cancer cells. Close follow-up will ensure that necessary therapy will be provided if needed according to clinical criteria. Results in terms of prostate size PSA level and tumor size will be recorded.

Official Title
-----------------
Selective Retrograde Venography and Sclerotherapy of Internal Spermatic Veins and Associated Venous Bypasses and Retro-Peritoneal Collateral in Patients With Bilateral Varicocele and Localized Prostate Cancer

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Procedure: venographic occlusion of spermatic veins


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males age 45-75 Prostate cancer Presence of varicocele No contraindication for venography Exclusion Criteria: Diseases or medications which prevent interventional vascular procedures

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Procedure: venographic occlusion of spermatic veins<br>* Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.<br>|
| No Intervention: 2<br>Watch-full follow-up | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety performance of the procedure. The change in tumor size and prostate cancer cells as evaluated by trans-rectal ultrasound and prostate biopsy |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change in size of the prostate as evaluated by ultrasound Change in PSA value. Reduction of above 20% in nocturia |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prostate cancer, venography, male patients, Localized microscopic prostate cancer up to Gleason 6 (3+3), PSA level <14, presence of varicocele
Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.

Detailed Description
-----------------
Randomized, double-blind, placebo-controlled, parallel-group, multi-centered, outpatient study to assess the efficacy, safety and tolerability of two doses of nalmefene in patients with current diagnosis of pathological gambling.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling

Conditions
-----------------
Pathological Gambling

Intervention / Treatment
-----------------
* Drug: nalmefene HCl
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Current diagnosis of pathological gambling as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Nalmefene HCl 20 mg | Drug: nalmefene HCl<br>* Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.<br>|
| Experimental: 2<br>Nalmefene HCl 40 mg | Drug: nalmefene HCl<br>* Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.<br>|
| Placebo Comparator: 3<br>Placebo | Other: Placebo<br>* Placebo tablet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess efficacy in treatment of pathological gambling |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate safety and tolerability in treatment of pathological gambling |  |  |